Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Disopyramide (INN, trade names Norpace and Rythmodan) is an antiarrhythmic medication used in the treatment of ventricular tachycardia. It is a sodium channel blocker and is classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the contractility. Disopyramide…
Standards, Side effects & Adverse effects
Explore the main themes, entities and connections around Disopyramide. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
effects patients ventricular used side lv treatment negative effect antiarrhythmic normal inotropic hcm systolic agent quinidine action obstructive also class
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Disopyramide | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Disopyramide | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Disopyramide | ATC code | C01BA03 (WHO) | 1.00 | infobox |
| Disopyramide | Bioavailability | High | 1.00 | infobox |
| Disopyramide | CAS Number | 3737-09-5 Y | 1.00 | infobox |
| Disopyramide | ChEBI | CHEBI:4657 Y | 1.00 | infobox |
| Disopyramide | ChEMBL | ChEMBL517 Y | 1.00 | infobox |
| Disopyramide | ChemSpider | 3002 Y | 1.00 | infobox |
| Disopyramide | CompTox Dashboard (EPA) | DTXSID1045536 | 1.00 | infobox |
| Disopyramide | DrugBank | DB00280 Y | 1.00 | infobox |
| Disopyramide | ECHA InfoCard | 100.021.010 | 1.00 | infobox |
| Disopyramide | Elimination half-life | 6.7 hours (range 4 to 10 hours) | 1.00 | infobox |
| Disopyramide | Excretion | Renal (80%) | 1.00 | infobox |
| Disopyramide | Formula | C21H29N3O | 1.00 | infobox |
| Disopyramide | IUPHAR/BPS | 7167 | 1.00 | infobox |
| Disopyramide | KEGG | D00303 Y | 1.00 | infobox |
| Disopyramide | Legal status | BR: Class C1 (Other controlled substances) | 1.00 | infobox |
| Disopyramide | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Disopyramide | Legal status | US: ℞-only | 1.00 | infobox |
| Disopyramide | MedlinePlus | a682408 | 1.00 | infobox |
| Disopyramide | Melting point | 94.5 to 95 °C (202.1 to 203.0 °F) | 1.00 | infobox |
| Disopyramide | Metabolism | Hepatic (CYP3A4-mediated) | 1.00 | infobox |
| Disopyramide | Molar mass | 339.483 g·mol−1 | 1.00 | infobox |
| Disopyramide | Pregnancy category | AU: B2 | 1.00 | infobox |
| Disopyramide | Protein binding | 50% to 65% (concentration-dependent) | 1.00 | infobox |
| Disopyramide | PubChem CID | 3114 | 1.00 | infobox |
| Disopyramide | Routes of administration | Oral, intravenous | 1.00 | infobox |
| Disopyramide | Trade names | Norpace | 1.00 | infobox |
| Disopyramide | UNII | GFO928U8MQ | 1.00 | infobox |
| Disopyramide | is a | reasonable approach before proceeding to invasive septal reduction | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.